EZH2 and melanoma: Besides, Zingg et al. showed that during anti-CTLA-4 or IL-2 immunotherapy in mice, intratumoral tumor necrosis factor-αproduction and T cell accumulation results in increased Ezh2 expression in melanoma cells, which in turn silences their own immunogenicity and antigen presentation.